Intestinal permeability in patients with yersinia triggered reactive arthritis

Rütta Lahesmaa-Rantala, Karl-Eric Magnusson, Kaisa Granfors, Rauli Leino, Tommy Sundqvist, Auli Toivanen

Abstract
The passive intestinal permeability of patients with yersinia triggered reactive arthritis was studied using different sized polyethylene glycols (PEGs) contained in a mixture of PEG 400 and PEG 1000. The investigation was carried out at least one year after the onset of yersinia infection, and patients had neither acute gastrointestinal nor joint symptoms. The control groups included patients with uncomplicated yersiniosis as well as healthy subjects who were either HLA-B27 positive or negative. An altered intestinal barrier function to PEG molecules was detected in patients with a history of yersinia infection compared with healthy controls. No significant differences in the permeability were found between patients with or without reactive arthritis, nor was there any association of increased permeability with HLA-B27. The passive permeability of the intestinal mucosa to the larger molecules was increased for an unexpectedly long time after the acute yersinia infection, probably contributing to the perpetuation of joint symptoms in subjects susceptible to a chronic joint disease.

A variety of intestinal disorders are linked with HLA-B27 associated arthropathies, including enteric arthritides triggered by yersinia, salmonella, shigella, and campylobacter as well as joint diseases following chronic inflammatory bowel diseases, ulcerative colitis, and Crohn’s disease.5 6 The association between klebsiella and ankylosing spondylitis indicates the role of the gut also in the pathogenesis of this rheumatic disease.5 6 Both microscopic and macroscopic gut lesions have been shown in enteric and idiopathic reactive arthritides as well as in ankylosing spondylitis, indicating subclinical bowel inflammation.5 6 It seems that disturbance of intestinal barrier function by infection may be an important factor in the development of joint symptoms.

Impaired ability of the gut mucosa to exclude different sized test molecules has earlier been reported in inflammatory bowel diseases and ankylosing spondylitis.5 6 Serrander et al found increased intestinal permeability in four patients with yersinia triggered reactive arthritis shortly after the onset of the infection10; patients with uncomplicated yersiniosis were not studied. In their patients permeability changes induced by infection returned to normal within about two months.

Obviously, acute gastrointestinal infection affects gut permeability. Genetic predisposition—for example, association with HLA-B27, might also have a role, however, predisposing either to chronic infection or to immunopathological events in the gut. Furthermore, the existence of a genetically abnormal gut mucosa remains a possibility.

Investigators are actively pursuing the question of whether or not the gut in patients with rheumatoid arthritis is intrinsically abnormal.11 So far, no clear supporting evidence exists. Reactive arthritis in which the triggering microbe is known offers a unique opportunity to distinguish between the role of infection and that of genetic predisposition in intestinal permeability. A study of reactive arthritis has a distinct advantage, compared with ankylosing spondylitis or rheumatoid arthritis, for example, in that controls who have had gastrointestinal disease without postinfection complication are available.

In our study the relative importance of HLA-B27 or a previous yersinia infection, or both, for intestinal permeability was studied. To avoid the influence of acute intestinal infection or drug treatment we studied a group of patients all symptomless at the time of investigation and having earlier had yersinia infection either uncomplicated or followed by reactive arthritis.

Patients and methods
PATIENTS AND CONTROLS
Sixteen patients with a history of infection caused by Yersinia enterocolitica O:3 were studied. The diagnosis of yersinia infection was based on significantly raised yersinia specific antibodies, measured by enzyme linked immunosorbent assay (ELISA),12 and a typical clinical picture. Y enterocolitica was isolated from the stools of nine patients. Eight of these patients (six men, two women; aged 40 (SD 12) years) had developed reactive arthritis after yersiniosis and were all tissue typed as HLA-B27. The other eight patients (six men, two women; aged 40 (11) years) had recovered from their gastrointestinal infection with no post-infection complications and were negative for HLA-B27 tissue antigen. The investigation was carried out at least one year after the onset of the patients’ infection, and all patients were clinically recovered from all gastrointestinal and joint symptoms. Consequently, test subjects were receiving no drugs. The controls included 18 healthy volunteers, 10 of whom were HLA-B27 positive (one man, nine women; aged 35 (16) years) and eight HLA-B27 negative (one man, seven women; aged 31 (7) years).
POLYETHYLENE GLYCOL ABSORPTION TEST
After an overnight fast test subjects were given a 200 ml liquid meal orally (oral rehydration fluid; Semper, Sweden) containing about 20 different sized polyethylene glycols (PEGs) in the mixture with 0.1 g of PEG 400 and 2.5 g of PEG 1000 (Macrogolom 400/1000; Apoteksbolaget, Sweden). Once an hour for the next six hours test subjects drank one glass of water during the urine collection period. Thereafter, the total urine volume was measured, and samples of urine were frozen at -20°C until analysis.

ANALYSIS OF PEG
This procedure used for extraction and analysis of the recovery of PEGs have been described elsewhere. Briefly, PEG was extracted from the urine samples with an Amberlite MB-3 anionic and cationic exchange resin. Thereinafter, the PEGs of different molecular weight were separated from each other by high performance liquid chromatography. Peaks (size range 238-1250 daltons in PEG 400-PEG 1000 mixture) were detected by a refractive index meter (HSRI 931; Tecator AB, Sweden).

DESCRIPTION OF THE INTESTINAL BARRIER
In addition to determining the percentage recovery of different sized PEGs in the urine during the six hour collection period, we further characterised the intestinal barrier by determining the maximum PEG recovery (Rmax; the highest observed percentage of PEG recovery in each subject) and the break point (representing the PEG size at which 50% of intestinal filtering of PEGs had occurred). The coefficient of variation between two independent measurements of intestinal permeability in healthy subjects has previously been shown to be more than 95% dependent on the size of the PEG. Statistical analysis of these variables was by Student’s t test. Further evaluation of the differences between the groups of patients was also made by comparing the sum of ranks for each patient, based on the relative urinary excretion of all sizes of PEG molecules or those >370 daltons.

Results
RECOVERY OF PEG MOLECULES IN SIX HOUR URINE SAMPLES
A slightly increased intestinal permeability was noted in HLA-B27 positive patients who had yersinia triggered reactive arthritis than in the HLA-B27 positive healthy controls (fig 1A). This was seen for PEG molecules of all different sizes, but the rank sum test disclosed no significant differences. Similarly, there were no differences between patients with reactive arthritis and those with uncomplicated yersiniosis (fig 1B). Thus the permeability was not dependent on the development of arthritis or on the presence of HLA-B27.

INTESTINAL FILTERING
Further analysis showed that permeability was increased most with respect to the larger test molecules. The table shows the characteristics describing the ability of the gut to exclude molecules owing to size. Break point values, describing the molecular weight at which 50% of the intestinal filtering occurs, tended to be higher in patients who had had yersinia infection than in healthy controls; the maximal recovery (Rmax; %) showed the same tendency (table). The size of the PEG at the point of maximal recovery was significantly greater

| Intestinal permeability characteristics in patients with a previous infection with Yersinia enterocolitica. Mean (SEM) is given for each variable. |
|----------------------------------|----------------|----------------|----------------|
| Group                           | Number of patients | Break point daltons | Maximal recovery at Rmax (%, daltons) | PEG size at Rmax (daltons) |
|----------------------------------|-------------------|-------------------|-------------------------------------|
| HLA-B27 positive                 |                   |                   |                                     |
| Reactive arthritis               | 8                 | 710 (27)          | 40-3 (7-1)                          | 546 (14)***               |
| Healthy controls                 | 10                | 704 (14)          | 32-2 (6-2)                          | 498 (12)                 |
|----------------------------------|-------------------|-------------------|-------------------------------------|
| HLA-B27 negative                 |                   |                   |                                     |
| Uncomplicated yersiniosis        | 8                 | 718 (19)          | 40-2 (2-3)                          | 563 (17)**               |
| Healthy controls                 | 8                 | 707 (15)          | 37-4 (4-0)                          | 519 (12)                 |

*p<0.025; **p<0.01.  
1PEG=polyethylene glycol.
Intestinal permeability in yersinia reactive arthritis

Discussion

In this study intestinal permeability tended to be greater in patients who had had yersinia infection than in controls who had not had yersinia infection (fig 1A). Surprisingly, the influence of infection, which was noted during the acute phase of infection and seemingly returned to normal after less than two months, could be still seen over one year after the onset of the disease. No greater increase in intestinal permeability was found, however, in patients who developed yersinia triggered reactive arthritis than in those with uncomplicated yersiniosis; nor was it linked to HLA-B27.

It is of interest to consider the reason(s) for the prolonged increased intestinal permeability of these patients compared with controls. Non-steroidal anti-inflammatory drugs, which are known to induce mucosal changes and increase intestinal permeability, cannot be the cause as none of the patients was receiving them. Whether this functional change in intestinal barrier is due to some chronic structural changes induced by acute infection, or whether there is a chronic latent inflammation developing after apparent recovery of the mucosal barrier remains an open question. Both macroscopic and microscopic changes have been found in patients with reactive arthritis as well as in those with acute gastroenteritis (Leirisalo-Repo, personal communication). There are, however, no follow up studies comparing patients with enterarthropathy and uncomplicated gastrointestinal infection which would show how long after the onset of infection these lesions can be seen.

At least two possible reasons might explain the chronic latent inflammation in patients—namely, persistence of yersinia antigens or prolonged changes in intestinal flora. Persistence of yersinia antigens in the host is suggested by the persistence and maturation of IgA responses in patients with yersinia triggered reactive arthritis and indicated also by the prolonged occurrence of immune complexes containing yersinia antigens. Recently, yersinia antigens have been found in gut biopsy specimens of patients with chronic infections. In some of these patients such antigen persistence might affect intestinal permeability. As for the second possibility, it is not yet known what kind of changes in the intestinal flora are induced by acute gastroenteritis. In rheumatoid arthritis the changes reported in intestinal microbial flora may affect gut permeability through inflammation. Combined disturbances in intestinal permeability and microbial flora may increase the antigenic load of gut associated lymphoid tissue and circulation, with potentially harmful consequences in susceptible subjects.

In normal uninfected subjects mainly small molecules are permitted through the mucosal barrier. In contrast, larger molecules seemed able to pass the intestinal barrier in patients with history of yersiniosis. Increased passage of molecules through the intestinal barrier was noted particularly for the larger molecules. A similar permeability profile has also been found in patients with Crohn’s disease, where with increasing frequency larger PEG molecules are allowed to pass the gut barrier. This might be explained by the similar localisation of gut inflammation in the two diseases.

Although an altered intestinal barrier function was shown in the patients studied, no joint symptoms were evident at the time of investigation. The present patient group did not include those with chronic joint symptoms, which are seen in about 10–20% of patients with yersinia reactive arthritis. Furthermore, about 50% had some minor problems, such as back pain. In experimental animal models the perpetuation of arthritis, once triggered, can be achieved by injecting a variety of antigens into genetically susceptible animals. Possibly, therefore, by allowing increased access to both microbial and dietary antigens, increased gut permeability to large molecules might have a
crucial role in the chronic aspect of arthritis. The essential question is whether or not gut is intrinsically abnormal in rheumatic diseases.11 Results presented herein suggest that this is not the case; at least in yersinia triggered reactive arthritis, an infection, rather than a predisposing intrinsic factor (HLA-B27 status), seems to have led to impaired intestinal barrier.

We thank Mrs Anita Sjö, and Ms Sari Tasa for skilful technical help, Dr Erik K Leander for statistical advice, and Dr Jeri L Hill for critical review of the manuscript. This study was supported by the Sigrid Jusélius Foundation, the Yrjö Jahnsson Foundation, King Gustaf Vth 80-Year Foundation, Professor Nanna Svartz Foundation, and the Swedish Medical Research Council (project No 6251).